Introduction
Prostate cancer is the most common cancer and the second leading cancer-related cause of death among males in Western societies. In the United States there were an estimated 170 000 new cases of prostate cancer diagnosed and 31 000 prostate cancer related deaths in 2000 (Lieberman et al., 2001) . Moreover, due to the increasing age in Western society, incidence rates are highly likely to increase even further. While the early stage prostate-confined disease is curable by surgery, locally advanced or metastatic tumors remain essentially incurable. Current protocols of treatment for advanced prostate cancer provide only short-term responses (Middleman et al., 1996) , and alternative therapies appear limited (Yagoda and Petrylak, 1993) . Medical or surgical androgen ablation remains the gold standard of treatment, however, the response is only transient and the majority develop androgen resistant disease within 2 -3 years. Understanding the events involved in tumor progression, including the functions of peptide growth factors and receptors and the relevance of their aberrant expression, is therefore of critical importance to identify new targets and strategies for novel treatment approaches.
Prostate carcinoma cells have been shown to express several growth factors and receptors, including fibroblast growth factors (FGFs) (e.g. Nakamoto et al., 1992; Yan et al., 1993) . Of the increasing number of structurally related polypeptides of the FGF family, several members have been detected in prostatic hyperplasia, prostate carcinoma and tumor cells, including FGF-2, FGF-7/KGF (Giri et al., 1999a; Mehta et al., 2000; Ropiquet et al., 1999) , FGF-6 (Ropiquet et al., 2000) , FGF-8 (Leung et al., 1996) and FGF-9 (Giri et al., 1999b) .
FGF-2 has attracted special attention because it acts as a powerful mitogen inducing differentiation and invasion of tumor cells, and exhibits angiogenic properties (Gospodarowicz et al., 1987) . In the normal prostate, it is found in only small quantities (Ittman and Mansukhani, 1997; Story et al., 1989 ) with 2 -3-fold higher levels measured in human benign prostate hyperplasia (Begun et al., 1995; Mori et al., 1990; Nishi et al., 1988) . More importantly, however, while organ-confined, low-grade prostate carcinoma cells express undetectable amounts of FGF-2 mRNA and protein, primary prostate cancer cells with distant metastasis to bone show a significant amount of FGF-2 mRNA and protein expression (Dow et al., 1997) . FGF-2 plays a major role in the differentiation of prostate cancer cells from a dormant to an invasive phenotype (Yan et al., 1993) , and it has been shown that FGF-2, as well as FGF-1, modulate prostate cancer cell proliferation (Dow and deVere White, 2000; Shain et al., 1996, for review) .
After secretion, FGFs are found to be tightly bound to the heparan sulphate proteoglycans in the extracellular matrix (ECM) which quenches their biological activity. One mechanism of releasing the active FGF-2 from the ECM is through binding to a secreted FGFbinding protein named FGF-BP (Czubayko et al., 1994; Wellstein and Czubayko, 1996) or HBp17 (Wu et al., 1991) . FGF-BP reversibly and noncovalently binds FGF-2, prevents its degradation and retains its mitogenic activity Wu et al., 1991) . The protein is highly homologous between human, mouse, rat and bovine species (Aigner et al., 2000b; Kurtz et al., 1997; Lametsch et al., 2000) and, although it is expressed in the adult in some normal tissues (Aigner et al., 2000b) , FGF-BP expression is more prominent during proliferative mechanisms like embryogenesis (Aigner et al., 2002) and wound healing (Aigner et al., submitted) as well as in tumor growth. FGF-BP was found to be expressed in a number of human squamous cell carcinoma (SCC) and colon cancer derived cell lines (Czubayko et al., 1994; Okamoto et al., 1996) and was shown to switch the non-tumorigenic FGF-2 expressing human cell line SW-13 to a tumorigenic and angiogenic phenotype in vitro and in vivo (Czubayko et al., 1994; LiaudetCoopman et al., 1996) . Depletion of endogenous FGF-BP by ribozyme-targeting in SCC and colon carcinoma cell lines reduced the release of biologically active FGF-2 from cells in culture and decreased both cell proliferation in vitro and tumor growth in vivo. In SCC xenografts in mice, downregulation of FGF-BP expression also revealed inhibition of angiogenesis indicating that FGF-BP can serve as an angiogenic switch molecule (Czubayko et al., 1997) . FGF-BP expression is increased during early stages of carcinogen-induced transformation in adult murine skin (Kurtz et al., 1997) and in a human skin xenograft model (Aigner et al., submitted) , is significantly upregulated by TPA, EGF or serum (Harris et al., 1998; and downregulated by retinoids in vitro and in vivo (Aigner et al., 2000b; . Recently, we also observed that the human papillomavirus (HPV) 16 E6 oncoprotein leads to increased FGF-BP expression in human keratinocytes (Sto¨ppler et al., 2001) .
The putative rate-limiting influence of FGF-BP on FGF-2 bioactivity and the role of FGF-2 in prostate tumor progression prompted us to study the significance of FGF-BP expression in prostate tumor cells.
We demonstrate that prostate carcinoma cell lines express high levels of FGF-BP. Downregulation of FGF-BP expression by specific ribozyme targeting results in reduced proliferation of the mass-transfected cells. Furthermore, reduction of FGF-BP levels by ribozymes completely abolishes the ability of high metastatic PC-3 cells to grow tumors in a subcutaneous nude mouse model. Using cDNA microarrays, Northern blotting and RT -PCR we show complex changes in the expression pattern between wild type and ribozyme transfected prostate carcinoma cells.
We conclude that even a partial reduction of FGF-BP in prostate carcinoma cells has a significant effect on in vitro proliferation and completely abolishes tumor growth in an in vivo mouse model. This result is far beyond the in vivo effects of FGF-BP ribozyme targeting observed in previous studies with other tumor cells in this model where only partial reduction of tumor growth was observed suggesting a high biological relevance of FGF-BP in prostate tumor biology.
Results

FGF-BP expression in prostate carcinoma cell lines
By Western blotting using polyclonal anti-(FGF-BP) antibodies (Aigner et al., 2000b; Czubayko et al., 1997) , we analysed FGF-BP expression in the cell lines PC-3, DU-145 and LNCaP. Lysates of all cell lines were positive for FGF-BP as indicated by a single strong band at 29 kDa (Figure 1) . No low molecular weight band at 17 kDa representing a C-terminally truncated FGF-BP as seen in other samples (Aigner et al., 2000b; Wu et al., 1991) was detected. FGF-BP levels in the supernatants were below the limit of detection.
FGF-BP depletion in DU-145 and PC3-3 cells by ribozyme targeting
The FGF-BP targeting ribozyme Rz332 was stably transfected into DU-145 and PC-3 prostate carcinoma Figure 1 Detection of FGF-BP protein by Western blotting in lysates of prostate carcinoma cell lines cells. After G418 selection, the mass-transfected cell lines DU-145 Rz and PC-3 Rz were screened for FGF-BP expression and compared to the parental wild type cell lines. Northern blotting revealed a significant reduction of FGF-BP by *55% in DU-145 and *66% in PC-3 cells upon ribozyme transfection (Figure 2a,b) . The decrease in FGF-BP mRNA was reflected by an even larger reduction of FGF-BP protein as shown by Western blotting (Figure 2c ).
FGF-BP and proliferation of prostate carcinoma cells
Anchorage-dependent proliferation of PC-3 prostate carcinoma cells was significantly reduced upon ribozyme-mediated downregulation of FGF-BP. Under normal growth conditions with medium containing 10% FCS, ribozyme activity lead to a marked reduction of PC-3 cell proliferation which was statistically significant after 2 days and reached *50% at day 5 (Figure 3, left) . Likewise, a decrease 
FGF-BP dependent colony formation
To determine anchorage-independent proliferation rates, we assayed for spontaneous colony formation in soft agar. PC-3 cells showed a *50% reduction in colony formation upon ribozyme-mediated downregulation of FGF-BP which correlates well with the data on anchorage-dependent proliferation (Figure 4a , right). Similar results were obtained with DU-145 cells indicating that in both cell lines ribozyme action affects anchorage-independent cell proliferation.
To address the question whether different FGF-BP expression levels exert an effect on FGF-2-mediated stimulation of cell proliferation, FGF-2 at different concentrations was added to the soft agar. DU-145 cells showed dose-dependent stimulation of spontaneous colony formation by FGF-2 which was independent of FGF-BP levels ( Figure 4b ). Addition of anti-(FGF-2) antibodies did not reduce colony formation of DU-145 wild type or ribozyme transfected cells. In contrast, FGF-2 did not stimulate colony formation of PC-3 cells. No differences between wild type or ribozyme transfected cells were observed ( Figure 4c ). Both observations were consistent with results from anchorage-dependent proliferation experiments with PC-3 cell grown on plastic (not shown). Interestingly, despite this lack of FGF-2-mediated stimulation of PC-3 cell proliferation, FGF-2 induced activation of the ERK cascade in PC-3 cells in a dosedependent manner. While basal levels of phosphorylated p42/44 were somewhat higher in ribozymetransfected as compared to wild type PC-3 cells, upon addition of FGF-2 strong induction of phosphorylation was seen which was very similar in both cell lines indicating that this effect is independent of FGF-BP levels (not shown).
Cell cycle analysis and apoptosis
We determined FGF-BP-dependent effects on cell cycle and apoptosis which may account for the different proliferation rates in vitro. Comparison of cell cycle distribution of wild type and ribozyme transfected cells by flow cytometry analysis after propidium iodide staining of nuclear DNA revealed no differences in PC-3 ( Figure 5a ) and DU-145 cells (not shown). Cyclins are the key components of the cell cycle progression machinery, and the discontinuous expression of several cyclins, occurring at discrete and well-defined periods of the cell cycle, can be used to identify cell cycle arrest or differences in cell cycle distribution. Quantification of the G 2 /M period by FACS analysis of cyclin B1 which shows peak expression in late G 2 /M confirmed the propidium iodide results in showing similar cell cycle distribution of wild type and ribozyme-transfected cells (not shown). Likewise, several experiments revealed similar rates of apoptosis as measured by histone-associated DNA fragment quantitation in wild type and ribozyme-transfected DU-145 or PC-3 cells with slight differences being statistically not significant (not shown). We conclude that different growth rates of cells, namely PC-3 cells, growing attached on a plastic surface under normal serum-containing conditions do not result from measurable differences in cell cycle or apoptosis.
Analysis of differential gene expression by microarray hybridization, Northern blot analysis and RT -PCR
Gene-expression analysis by cDNA microarray hybridization identified 99 transcripts that were altered in the ribozyme transfected PC-3 cells in contrast to only 13 changes in the ribozyme transfected DU-145 cells (Figure 6a ). Ubiquitin carboxyl-terminal esterase (UCHL-1/PGP 9.5) and HER-2 interacting protein (ERBIN) were *8-and *3.5-fold upregulated in the microarray analysis of PC-3 ribozyme transfected cells. Northern analysis (Figure 6b ) and RT -PCR ( Figure  6c , upper panel) confirmed the observed differential expression of both genes in the ribozyme transfected versus wild type PC-3 cells. The expression of these genes did not change in DU-145 wt versus ribozyme transfected cells.
Additionally, expression of the placental bone morphogenetic protein (PLAB), which is expressed in the prostate and possibly plays a role in prostate cancer metastasis to the bone, and of interleukin-8 (IL-8) was analysed since for both proteins a function in prostate cancer has been suggested. RT -PCR (Figure 
Discussion
In this study we show the relevance of a secreted FGFbinding protein (FGF-BP) in prostate carcinoma cell lines in vitro and their subcutaneous tumor growth in vivo. We demonstrate by Western blotting that FGF-BP is expressed in all prostate carcinoma cell lines tested which is in agreement with preliminary immunohistochemical data indicating elevated FGF-BP expression in the transformed epithelia of malignant prostate tumors (Aigner et al., unpublished data) . The absence of FGF-BP in cellular supernatants is consistent with previous results in other cell lines and may reflect low FGF-BP secretion or poor stability of the secreted protein which is also observed in various other in vitro experiments (Aigner et al., unpublished data) .
For our studies, we selected the highly metastatic cell line PC-3 and the weakly metastatic cell line DU-145. Previously, conflicting data were published on FGF-2 expression in these cell lines with Nakamoto et al. (1992) showing FGF-2 mRNA and protein expression in PC-3 and DU-145 cells while Chandler et al. (1999) failed to detect FGF-2 mRNA in either cell lines. Therefore, we performed FGF-2 ELISA experiments and clearly found FGF-2 expression in both cell lines in the range of 500 pg FGF-2/mg total cellular protein (data not shown).
We used a ribozyme directed against the open reading frame of FGF-BP mRNA which had previously been shown to efficiently cleave FGF-BP mRNA in other cells (Czubayko et al., 1997) . Stable transfections resulted in a 450% downregulation of FGF-BP mRNA levels in both mass-transfected cell lines which was reflected by an even more prominent *80% reduction of FGF-BP protein levels in DU-145 cells. Depletion of FGF-BP in PC-3 cells resulted in a marked inhibition of anchorage-dependent proliferation and anchorage-independent colony formation which was very comparable in both experiments and identifies FGF-BP as rate-limiting factor for cell proliferation. While in DU-145 cells no differences in proliferation on plastic were observed, soft agar colony formation which resembles the in vivo situation more closely again revealed a *50% reduction similar to the results in PC-3 cells. Addition of exogenous FGF-2 to soft agars lead to stimulation of DU-145, but not of PC-3 cells, which is consistent with previous data (Chackal-Roy et al., 1989; La Rocca et al., 1991; Nakamoto et al., 1992) and may result from differences between the cell lines in post receptor signal transduction (Nakamoto et al., 1992) . Nevertheless, FGF-2-induced activation of the ERK cascade was observed in PC-3 cells. Most interestingly, in DU-145 and in PC-3 cell lines the ERK activation in response to exogenous FGF-2 was independent of intracellular FGF-BP levels since comparison of wild type and ribozyme-transfected cells showed identical results. Likewise, addition of inactivating anti-(FGF-2) antibodies did not reduce colony formation, again independently of endogenous FGF-BP levels. The most likely explanation is that FGF-BP acts in prostate carcinoma cells through another growth factor rather than FGF-2. Currently, we are investigating this aspect by screening various other members of the FGF family for protein -protein interactions with FGF-BP and the biological significance of these findings with regard to FGF bioactivity. Very recent results from our laboratory indicate that FGF-BP is indeed able to bind FGF-4 and FGF-10 (Aigner et al., unpublished data). Concomitantly, it was shown recently by overexpression of dominant negative FGF-receptor mutants that FGFR-1 signaling is important in the survival of PC-3, DU-145 and LNCaP cell lines (Ozen et al., 2001) . Taken together, these findings strongly indicate the possibility that an FGF family member other than FGF-2 may be involved in prostate cancer. Furthermore, it is possible that (1) FGF -BP acts primarily on endogenous FGF-2 which is expressed in both cell lines in large amounts and which upon secretion is immobilized in the ECM, and/or (2) FGF-BP acts intracellularly on FGF-2 through a yet unknown mechanism e.g. facilitating release of FGF-2 which lacks a classic signal peptide for secretion.
To further define the cellular effects of FGF-BP deprivation, cell cycle distribution and apoptosis were determined. Flow cytometry analysis revealed no Figure 7 Tumor growth of PC-3 wt and FGF-BP-depleted (PC-3 Rz) prostate carcinoma cells in vivo. Cells were injected subcutaneously into both flanks of athymic nude mice and visible tumors were measured regularly. Experiments were done twice with at least seven tumors/group and in both experiments tumor growth was abolished in FGF-BP-depleted cells. Shown are mean tumor areas+s.e.m differences between wild type and ribozyme-transfected cells in both PC-3 and DU-145 cell lines indicating that reduction of FGF-BP expression levels do not exert an effect on cell cycle distribution in cells grown on plastic. Likewise, in both cell lines no statistically significant alterations in apoptosis were observed upon ribozyme-mediated FGF-BP reduction. This is also in agreement with our results from the cDNA microarray analysis (see below) which did not reveal significant differences in gene expression of cell cycle or apoptosis genes upon ribozyme transfection. While in DU-145 cells these results are in agreement with the identical growth rates of wild type and ribozyme-transfected cells when grown on plastic, they do not explain the observed ribozyme-mediated approximately 50% decrease of in vitro PC-3 cell proliferation. We speculate that either this effect is mediated through other mechanisms or that effects of ribozyme-mediated FGF-BP deprivation on cell cycle and/or apoptosis are below the limit of detection in our assays. In this case, differences between wild type and ribozyme-transfected cells may be stronger in the in vivo situation as seen also in the growth characteristics.
cDNA microarray hybridization studies for analysis of differential expression between wild type and ribozyme transfected cells reflected major changes in PC-3 cells but only limited regulation of gene expression in the DU-145 cells upon ribozymemediated FGF-BP deprivation. This difference might reflect the clonal heterogeneity of prostate cancer and/ or the origin of the cell lines from two different patients with advanced prostate carcinoma. Also, the PC-3 cell line was derived from a bone metastastic site whereas the DU-145 cell line was established from a brain metastatic lesion (Webber et al., 1997, for review) . The fact that they exhibit major differences in their karyotype and chromosome abnormalities (Bokhoven et al., 2001) could also contribute to the divergent rather than parallel changes in gene expression which we observed. Most prominent was the upregulation of UCHL-1/PGP 9.5 and of ERBIN in FGF-BP ribozyme-transfected PC-3 cells. These results were confirmed by Northern blotting and by RT -PCR. UCHL-1/PGP 9.5 is localized in the normal prostate gland in neuroendocrine as well as secretory cells and it is contributing to prostate secretions (Aumuller et al., 1999; Martin et al., 2000) . However, its precise physiological role in this organ is not known so far. The importance of ERBIN for the cellular localization and signaling of HER-2, a member of the EGF receptor family, in epithelial cells was recently described (Borg et al., 2000) . The actual function of ERBIN in cell homeostasis and carcinogenesis as well as the function of both proteins in prostate tumors remain to be elucidated.
We also analysed mRNA levels of potentially interesting gene products which are not represented on the cDNA microarray. IL-8 has been shown to be expressed in PC-3 cells and to be associated with tumorigenicity, metastasis and angiogenesis (Inoue et al., 2000; Kim et al., 2001 ). Here we found marked IL-8 downregulation in PC-3 cells upon ribozyme-mediated FGF-BP abrogation which may contribute to the decreased growth rate of our ribozyme-transfected cells and is therefore also in accordance with earlier studies (Inoue et al., 2000; Kim et al., 2001) . Notably, since we used mass-transfected cells rather than clones we can rule out any interference of the previously described natural IL-8 heterogeneity of PC-3 cells (Kim et al., 2001 ) with the FGF-BP ribozyme-mediated alterations of growth behavior observed in our study. Marked downregulation in PC-3 cells was also observed for the placental bone morphogenetic protein (PLAB) which is expressed in the prostate and possibly plays a role in prostate cancer metastasis to the bone (Thomas et al., 2001) .
In vivo studies revealed that the most dramatic effect of ribozyme-mediated FGF-BP deprivation was observed in subcutaneous tumor growth. The 60% reduction of FGF-BP mRNA completely prevented highly metastatic and tumorigenic PC-3 cells from tumor formation except for one very small tumor. This effect by far exceeds the results of earlier studies in squamous cell carcinoma and colon tumor cells in the same in vivo model where under stimilar conditions only a partial reduction of in vivo tumor growth was observed (Czubayko et al., 1997) . It will be interesting to conduct further studies to elucidate if this strong effect in the mouse model also translates into a ratelimiting role of FGF-BP in prostate tumor growth. Also, since the in vivo effects observed here are even more prominent than our in vitro data suggested, it is clearly possible that FGF-BP deprivation displays two synergistic effects in vivo: (i) decrease in autocrine or paracrine growth stimulation of tumor cells as observed in vitro, and (ii) reduced angiogenic activity of FGF-BP which normally acts as 'angiogenic switch molecule' (Czubayko et al., 1997) .
In summary, in this study we identify FGF-BP to be relevant in prostate cancer cells as a rate-limiting factor of tumor cell proliferation in vitro and of subcutaneous tumor growth in vivo. Precise evaluation of its clinical value requires immunohistochemical screening of a large number of prostate carcinomas which is currently under way, as well as extending the in vivo studies to the prostate itself. The latter project will elucidate if FGF-BP downregulation is able to abolish prostate tumor growth with similarly profound effects as in our experiments which exceeded earlier in vivo results with cell lines from other tumor entities. In this case, FGF-BP would clearly appear to be an attractive target molecule for prostate cancer therapy.
Materials and methods
Generation of constructs
Construction of the expression vector for a ribozyme designed to cleave 332 nucleotides downstream of the translation initiation site was described earlier (Czubayko et al., 1997) . Briefly, synthetic sense and antisense oligonucleotides containing the catalytic center and the flanking regions of the ribozyme were annealed and ligated into the HindIII/NotI sites of the pRc/CMV plasmid (Invitrogen) that also contains a G418 drug-resistance gene and expresses the ribozymes under the control of a cytomegalovirus (CMV) promoter.
Cell lines and transfection
Prostate carcinoma cell lines (American Type Culture Collection (ATCC), Rockville, MD, USA) were cultured in IMDM (DU-145, LNCap) or RPMI (PC-3), respectively, with 10% fetal calf serum at 37ºC in 5% CO 2 . DU-145 and PC-3 cells were transfected at 50% confluency with 20 mg of plasmid DNA mixed with 140 ml LipofectAmine reagent in serum free-medium for 5 h (IMDM, Life Technologies) under the same conditions. The transfection medium was then replaced with fresh medium and 36 h later G418 (1000 mg/ml) was added to select stably transfected cells during 4 -6 weeks of culture in the presence of the drug.
Northern blot analysis
Total RNA was isolated using the Tri reagent method with commercially available reagents and protocols (Sigma, Deisenhofen, Germany). Northern blots were performed essentially as desribed previously (Aigner et al., 2000b) . Briefly, 20 mg total RNA was separated in a 1% formaldehyde agarose gel and transferred to a nylon membrane (Hybond-N, Amersham Pharmacia Biotech, Buckinghamshire, UK) by capillary action. After pre-hybridization in 66SSC (0.9 M sodium chloride, 0.09 M sodium citrate, pH 7.0), 0.5% (w/v) SDS, 56Denhardt's solution (0.1% (w/v) Ficoll, 0.1% (w/v) polyvinylpyrrolidone, 0.1% bovine serum albumin, 100 mg/ml salmon sperm DNA) for 4 h at 48C, the membrane was hybridized overnight with a a-32 PdCTP-labelled (Rediprime, Amersham Pharmacia Biotech) human FGF-BP, human UCHL-1/PGP9.5 or human ERBIN cDNA probe, respectively, in the same buffer. The membrane was washed at 428C two times for 10 min in 26SSC/0.1% SDS and two times for 15 min with 0.16SSC/0.1% SDS and was then autoradiographed using intensifying screens at 7708C for 24 -96 h. For quantitation, the membrane was stripped at 958C in 0.026SSC/0.1% SDS for 5 min and reprobed with a glyceraldehyde-3-phosphate dehydrogenase (GAPDH) or 18S cDNA as a loading control.
RT -PCR
Of the total RNA 1.5 mg was reversely transcribed in a final volume of 20 ml using Superscript II and oligo-dT primer (GIBCO -BRL). RT -PCR was performed in a total volume of 50 ml containing 2 ml of the cDNA and 50 pmol of each primer (948C 5 min followed by 35 cycles 948C 30 s, 608C 30 s, 728C 30 s). Five ml aliquots were taken after 25, 30 and 35 cycles, respectively, and electrophoresed on a 1.5% ethidium bromide-stained agarose gel. Intron-spanning GAPDH primer pairs served as control. GAPDH: sense 5'-accacagtccatgccatcac/as 5'-tccaccaccctgttgctgta; UCHL-1/PGP9.5: sense 5'-cccgagatgctgaacaaagt/as 5'-aagcggacttctccttgctc; ERBIN: sense 5'-tcaggcctcaggcaaattat/as 5'-tggtccttcaggttgtaccc; PLAB sense 5'-tcagagttgcactccgaaga/as 5'-agagatacgcaggtgcaggt and Interleukin-8: sense 5'-gtctggaccccaaggaaaac/as 5'-attgcatctggcaaccctac.
Western blotting
One hundred thousand cells were cultured for 2 days under normal conditions, washed twice with PBS and lysed in 100 ml 1% SDS. After sonication and boiling, the lysate was centrifuged at 12 000 r.p.m. in a microcentrifuge for 5 min at room temperature. FGF-BP Western blotting was performed essentially as described previously (Aigner et al., 2000b) . Briefly, 25 ml of lysates were separated on a denaturating, reducing 12.5% polyacrylamide gel and transferred onto a nitrocellulose membrane (Protran BA 83, Schleicher & Schuell, Dassel) at 25 V for 45 min using Tris-glycine transfer buffer without methanol. After blocking with 5% skim milk powder, the membrane was washed with TBST (TBS/0.05% Tween-20) and probed with affinity purified rabbit antibodies raised against a GST-human FGF-BP fusion protein (Aigner et al., 2000b; Czubayko et al., 1997) in the same buffer at room temperature. After washing with TBST, bound antibodies were visualized by chemiluminescence using HRP-conjugated goat anti-rabbit antibodies (ECL, Amersham Pharmacia Biotech).
Proliferation assays and apoptosis
Studies of anchorage-dependent proliferation of PC-3 and DU-145 cell lines were carried out essentially as described previously (Aigner et al., 2000a) . Briefly, cells were plated in quadruplicates in 96 well plates at 500 and 1000 cells/well and cultivated in a humidified incubator under standard conditions in the presence or absence of 10% FCS. On a daily basis, cell numbers were assessed using a colorimetric assay which is based on the cleavage of the tetrazolium salt WST-1 by mitochondrial dehydrogenases in viable cells, according to the manufacturer's protocol (Cell Proliferation Reagent WST-1, Boehringer Mannheim) and as described previously (Aigner et al., 2000a) . For comparison of the transfected and nontransfected cell lines, the highest absorbance was defined as 100% and all other values were normalized accordingly. For comparison of the different growth curves at different time points, Student's unpaired t-test was performed.
Studies of anchorage-independent proliferation of the cell lines were carried out as described (Wellstein et al., 1990) . Briefly, 20 000 cells in 0.35% agar (Bacto Agar, Becton Dickinson) were layered on top of 1 ml of a solidified 0.6% agar layer in a 35 mm-dish. Growth media with 10% FCS were included in both layers. Colonies more than 50 mm in diameter were counted after 2 -3 weeks of incubation by at least two independent investigators. Apoptosis was measured using the Cell Death Detection ELISA (Roche Diagnostics, Mannheim, Germany) according to the manufacturer's protocol. Thirty thousand cells were plated in 12-wells in triplicates and grown for 2 days, washed once with PBS, trypsinized and assayed by ELISA for cytoplasmic histon-associated DNA fragments. For additional control of equal loading amounts of the samples, cell numbers were again determined by re-plating a small fraction into 96-wells and subsequent quantitation using WST-1 cell proliferation reagent (Roche).
Flow cytometry analysis
Cell sample preparation and propidium iodide staining for flow cytometry analysis were performed as described previously (Darzynkiewicz et al., 1992) . Briefly, cells were grown for 2 days under normal conditions, harvested by trypsinization and washed twice with PBS, followed by fixation in 70% ethanol diluted in PBS. Cells were then incubated in PBS containing 100 mg/ml RNase and 40 mg/ml propidium iodide at 378C for 1 h before flow cytometry analysis. Cell cycle distribution was determined using a FACS Calibur (Becton-Dickinson) with an argon laser set to excite at 488 nm. The results were analysed using Cell-Quest software.
Microarray fabrication
A non-redundant set of 6000 prostate-derived cDNA clones was identified from the Prostate Expression DataBase (PEDB, www.pedb.org), and a public sequence repository of expressed sequence tag (EST) data was derived from human prostate cDNA libraries. In brief, individual clone inserts were amplified by PCR and the purified products were mechanically 'spotted' onto poly-lysine coated microscope slides using an OmniGrid high-precision robotic printer (GeneMachines).
Probe construction and microarray hybridization
Thirty mg of total RNA was reverse transcribed using Superscript II (GIBCO -BRL) with 5-(3-aminoallyl)-2'-deoxyuridine-5'-triphosphate (aa-dUTP; Sigma-Aldrich) being added to the reaction mixture. The RNA was hydrolyzed and neutralized, and the cDNA was purified using Micron 30 filters (Millipore). After drying, it was resuspended in 4.5 ml of dH 2 O, and either Cy3 or Cy5 monoreactive fluorophors (Amersham Life Sciences) were used to label the cDNA-incorporated aminoallyl linker. After stopping of the reaction, probes of wild type and ribozymetransfected cells were combined and unincorporated Cy dyes were removed using the Qiaquick PCR Purification Kit (Qiagen). The probes were concentrated to 18 ml, combined with 3.6 ml 206SSC and 1.8 ml 10 mg/ml Poly(A) + . After heat denaturation at 1008C for 2 min the mixture was applied to a microarray slide with a coverslip and hybridized in a human chamber at 638C for 16 h. Slides were washed once with 16SSC, 0.03% SDS at RT for 2 min, 16SSC at RT for 1 min, once with 0.26SSC at RT for 20 min, and finally with 0.056SSC at RT for 10 min, were then rinsed in dH 2 O to remove any residual salts and dried.
Image acquisition and data analysis
A fluorescence image of the microarray was collected at both emission wavelengths using a GenePix 4000 fluorescent scanner (Axon Instruments) and analysis was performed using GenePix Pro Microarray Acquisition and Analysis Software. For each experiment, each cDNA was represented twice on each slide, and the experiments were performed in duplicate producing four data points per cDNA clone per hybridization probe. Intensity ratios for each cDNA clone hybridized with probes derived from the respective cell lines were calculated as log 2 (mac25 intensity/control intensity). Gene expression levels were considered significantly different between wild type and ribozyme transfected cells if at least three of the four replicate spots for a given cDNA demonstrated an average log 2 ratio of 40.66 or 570.66, and the signal intensity was greater than two standard deviations above the image background.
Tumor growth in animals
One and a half million PC-3 wild type or PC-3 Rz cells, respectively, in 100 ml of growth medium were injected into two subcutaneous sites on the flanks of athymic nude mice (female NCr nu/nu, at least seven tumors per group). Tumor growth was observed for 3 months and tumor sizes were regularly estimated from the product of the perpendicular diameters of the tumors.
Abbreviations ECM, extracellular matrix; EGF, epithelial growth factor; ELISA, enzyme-linked immunosorbent assay; ERBIN, HER-2 interacting protein; FACS, fluorescence-activated cell sorting; FCS, fetal calf serum; FGF, fibroblast growth factor; FGF-BP, fibroblast growth factor-binding protein; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; GST, glutathione S-transferase; HRP, horseradish peroxidase; IL-8, interleukin-8; PLAB, placental bone morphogenetic protein; Rz, ribozyme; SCC, squamous cell carcinoma; TPA, 12-Otetradecanoylphorbol-13-acetate; UCHL-1/PGP 9.5, ubiquitin carboxy-terminal esterase.
